Pyxis Oncology (PYXS) Announces Dosing of First Subject in Phase 1 Trial of PYX-201, a Novel ADC for Solid Tumors streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
23.12.2022 - CAMBRIDGE, Mass., Dec. 23, 2022 (GLOBE NEWSWIRE) - Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next-generation therapeutics to target difficult-to-treat cancers, reported on December 23, 2022 that Pyxis .
Pyxis Oncology Announces FDA Clearance of Two IND Applications streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.